Oryzon announces First-Patient-in in ALICE: a Phase IIa clinical trial with Iadademstat (ORY-1001) in Acute Myeloid Leukemia patients

MADRID, SPAIN and CAMBRIDGE MA.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today the inclusion of the first patient in a Phase IIa clinical study with Iadademstat (ORY-1001) in elderly Acute Myeloid Leukemia (AML) patients not eligible for intensive chemotherapy.

Click here to see the full Press Release